Results 41 to 50 of about 303,882 (203)
Teprotumumab for Thyroid Eye Disease: Efficacy and Impact on Orbital Decompression Utilization
Teprotumumab has been proven effective in thyroid eye disease and associated exophthalmos management. Since its FDA approval in 2020, teprotumumab therapy has been a popular choice for managing exophthalmos which has resulted in decreased utilization of orbital decompression surgery, from 36.8% between 2015 and 2020 to 11.1% TED patients between 2020 ...
Nitish Kumar +5 more
wiley +1 more source
Exploring tear fluid biomarkers and the ocular surface in thyroid eye disease
Abstract Purpose To examine ocular surface changes and inflammatory tear fluid biomarkers in patients with thyroid eye disease (TED). Methods We included 106 Graves' disease (GD) patients (36 without TED, 32 with active and 38 with inactive TED) and 106 age‐ and sex‐matched healthy subjects for ophthalmological evaluation, including ocular surface ...
Mikael Thomassen Neset +13 more
wiley +1 more source
Endocrine ophthalmopathy (EOP) is a chronic disease characterized by progressive autoimmune inflammation of the soft retrobulbar tissues in thyroid dysfunction.
Elizaveta S. Taskina +1 more
doaj +1 more source
TSHR‐Targeting Nucleic Acid Aptamer Treats Graves' Ophthalmopathy via Novel Allosteric Inhibition
This study presents YC3, a novel inhibitory TSHR‐targeting aptamer, as a promising therapeutic for Graves' ophthalmopathy (GO). YC3 suppresses pathological phenotypes in human orbital fibroblasts and improves outcomes in GO mice by binding to a previously unidentified allosteric site on TSHR, demonstrating the potential of aptamers in advancing ...
Yanchen Zhang +16 more
wiley +1 more source
A Pruritic Predicament: An Unusual Presentation of Graves’ Disease Complicated by Pregnancy
Pruritus is a known but uncommon symptom of hyperthyroidism that can be misinterpreted or overlooked in a patient presentation. This is a case report of a 40‐year‐old female who presents with a 3‐month history of severe, worsening pruritus. Further history demonstrated potential signs of hyperthyroidism, and laboratory values demonstrated low TSH ...
Rob Lawless +4 more
wiley +1 more source
Lugol’s Iodine as a Key Treatment in Transient Gestational Thyrotoxicosis: A Case Report
Introduction Transient gestational thyrotoxicosis (TGT) occurs when human chorionic gonadotropin (hCG) directly stimulates the maternal thyroid gland during the first trimester of pregnancy. We report a case of complicated TGT in a young woman who required treatment with Lugol’s solution.
Mariam Mabrouk +7 more
wiley +1 more source
A hard pill to swallow: a qualitative study of women’s experiences of adjuvant endocrine therapy for breast cancer [PDF]
Objective: To explore women’s experiences of taking adjuvant endocrine therapy as a treatment for breast cancer and how their beliefs about the purpose of the medication, side effects experienced and interactions with health professionals might influence
McCowan, Colin +16 more
core +1 more source
Background Tirzepatide is a dual agonist of the glucose‐dependent insulinotropic polypeptide (GIP) receptor and glucagon‐like peptide‐1 (GLP‐1) receptor, demonstrates significant efficacy in lowering blood glucose levels and reducing body weight. Consequently, its use has increased among patients with type 2 diabetes and obesity.
Yusuke Deto +8 more
wiley +1 more source
Prospects for targeted therapy of Graves' disease: A review [PDF]
The high prevalence of autoimmune thyroid diseases and the low effectiveness of treatment are the great of the reasons for long-term disability and high disability of patients.
Oksana V. Maksim +2 more
doaj +1 more source
Background Xiehuo Pingtu San (XHPTS) has been shown to be safe and effective in treating thyroid eye disease (TED), yet its underlying mechanisms remain unclear. This study aimed to elucidate the active ingredients of XHPTS and their therapeutic mechanisms in TED through network pharmacology, molecular docking, and molecular dynamics simulations ...
Ping Wang +6 more
wiley +1 more source

